Ayala Pharmaceuticals, Inc. Common Stock

REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting, taking place in-person November 16-19 in Vancouver, Canada.

Related tickers: AYLA.

Upgrades Morgan Stanley upgraded the previous rating for Pure Storage Inc (NYSE:PSTG) from Equal-Weight to Overweight. In the second quarter, Pure Storage showed an EPS of $0.32, compared to $0.14 from the year-ago quarter. The current stock performance of Pure Storage shows a 52-week-high of $36.71 and a 52-week-low of $21.89. Moreover, at the end of the last trading period, the closing price was at $30.50. According to Oppenheimer, the prior rating for Biomarin Pharmaceutical Inc (NASDAQ:BMRN) was changed from Perform to Outperform. In the third quarter, Biomarin Pharmaceutical showed an EPS of $0.04, compared to $0.20 from the year-ago quarter. The current stock performance of Biomarin Pharmaceutical shows a 52-week-high of $97.76 and a 52-week-low of $70.73. Moreover, at the end of the last trading period, the closing price was at $86.77. Barclays upgraded the previous rating for Intel Corp (NASDAQ:INTC) from Underweight to Equal-Weight. For the third quarter, Intel had an EPS of $0.59, compared to year-ago quarter EPS of $1.71. The current stock performance of Intel shows a 52-week-high of $56.28 and a 52-week-low of $24.59. Moreover, at the end of the last trading period, the closing price was at $29.07. According to Barclays, the prior rating for Gilead Sciences Inc (NASDAQ:GILD) was changed from Underweight to Equal-Weight. In the third quarter, Gilead Sciences showed an EPS of $1.90, compared to $2.65 from the year-ago quarter. The stock has a 52-week-high of $79.61 and a 52-week-low of $57.16. At the end of the last trading period, Gilead Sciences closed at $79.27. JP Morgan upgraded the previous rating for TrueCar Inc (NASDAQ:TRUE) from Underweight to Overweight. TrueCar earned $0.12 in the second quarter, compared to $0.07 in the year-ago quarter. At the moment, the stock has a 52-week-high of $4.08 and a 52-week-low of $1.30. TrueCar closed at $1.52 at the end of the last trading period. See all analyst ratings upgrades.   Downgrades Oppenheimer downgraded the previous rating for Ayala Pharmaceuticals Inc (NASDAQ:AYLA) from Outperform to Perform. Ayala Pharmaceuticals earned $0.54 in the second quarter, compared to $0.75 in the year-ago quarter. The current stock performance of Ayala Pharmaceuticals shows a 52-week-high of $9.40 and a 52-week-low of $0.57. Moreover, at the end of the last trading period, the closing price was at $0.69. Roth Capital downgraded the previous rating for Argo Blockchain PLC (NASDAQ:ARBK) from Neutral to Sell. Argo Blockchain earned $0.82 in the second quarter, compared to $0.03 in the year-ago quarter. At the moment, the stock has a 52-week-high of $13.14 and a 52-week-low of $1.37. Argo Blockchain closed at $1.97 at the end of the last trading period. According to Raymond James, the prior rating for Aon PLC (NYSE:AON) was changed from Market Perform to Underperform. Aon earned $2.02 in the third quarter, compared to $1.74 in the year-ago quarter. At the moment, the stock has a 52-week-high of $341.98 and a 52-week-low of $246.21. Aon closed at $289.20 at the end of the last trading period. According to Wells Fargo, the prior rating for Hanesbrands Inc (NYSE:HBI) was changed from Overweight to Underweight. In the second quarter, Hanesbrands showed an EPS of $0.28, compared to $0.47 from the year-ago quarter. At the moment, the stock has a 52-week-high of $17.55 and a 52-week-low of $6.91. Hanesbrands closed at $7.20 at the end of the last trading period. According to Wedbush, the prior rating for Y-mAbs Therapeutics Inc (NASDAQ:YMAB) was changed from Outperform to Neutral. For the second quarter, Y-mAbs Therapeutics had an EPS of $0.94, compared to year-ago quarter EPS of $0.53. At the moment, the stock has a 52-week-high of $20.48 and a 52-week-low of $6.50. Y-mAbs Therapeutics closed at $8.93 at the end of the last trading period. For Advanced Micro Devices Inc (NASDAQ:AMD), Northland Capital Markets downgraded the previous rating of Outperform to Market Perform. For the second quarter, Advanced Micro Devices had an EPS of $1.05, compared to year-ago quarter EPS of $0.63. The stock has a 52-week-high of $152.42 and a 52-week-low of $54.57. At the end of the last trading period, Advanced Micro Devices closed at $62.01. For Cedar Fair LP (NYSE:FUN), Credit Suisse downgraded the previous rating of Outperform to Neutral. Cedar ...Full story available on Benzinga.com

Related tickers: IMO, SLDP, GEF, IPSC, ABCB, ACLX, HBI, CDAY, AMGN, STRY, HON, KDP, BMRN, PBR, GRTS, DELL, RGA, YMAB, GILD, SON, OTLK, GSAT, AON, HCAT, HTBK, LYB, AYLA, INTC, CTGO, VTRU, NTAP, PARA, BMBL, TXRH, VEEV, DOCS, DTM, AMD, TRUE, FREY, CAT, PSTG, PRCT, CFR, SES, ARBK, DVA, SMBK, TSVT, FUN, IOVA.